The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.
Abstract
PURPOSE: It has been observed previously in osteosarcoma (OS) that the degree of necrosis of the resected primary tumor following a period of preoperative chemotherapy is predictive of subsequent event-free survival (EFS). The aim of this study was to determine if more intensive preoperative chemotherapy would increase the proportion of patients with a good histologic response and improve EFS. PATIENTS AND METHODS: Seventy-three patients with OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on the T12 protocol between 1986 and 1993. Patients were randomized between therapy based on the T10 protocol and therapy with more intensive preoperative chemotherapy. The more intensive preoperative regimen consisted of two courses of cisplatin (CDDP) and doxorubicin (DOX) in addition to the usual preoperative regimen of high-dose methotrexate (HD MTX) and bleomycin, cyclophosphamide, and dactinomycin (BCD). RESULTS: The regimen with more intensive preoperative chemotherapy achieved a modest increase in the proportion of patients with a good histologic response (44% with a grade III or IV histologic response v 37% in the control arm, 33% with grade IV histologic response v 13% in the control arm). EFS continued to correlate with histologic response. The actuarial 5-year EFS in patients with localized disease was 78% for the regimen with more intensive preoperative chemotherapy and 73% for the control arm. CONCLUSION: Despite modest increases in the proportion of patients with good histologic response with intensified preoperative chemotherapy, no improvement in EFS was observed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dosage of chemotherapy given before surgery shifts the degree of necrosis but it does not change the prognostic value of necrosis grading nor influence survival 119 .”
From Osteosarcoma (2022) · cites this paper as [119]
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B. M., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6 · Cited by 1,082
Self-citationChemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Lane, J. M., Marcove, R. C., Applewhite, A., Vlamis, V., & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 675
Self-citationPrimary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 584
Self-citationAdjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
Eilber, F. R., Giuliano, A. E., Eckardt, J. J., Patterson, K., Moseley, S. H., & Goodnight, J. E. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.21 · Cited by 524
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Provisor, A. J., Ettinger, L. J., Nachman, J. B., Krailo, M., Makley, J. T., Yunis, E. J., Huvos, A. G., Betcher, D. L., Baum, E. S., Kisker, C. T., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.76 · Cited by 458
Self-citationWinkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 457
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Applewhite, A., Sun, M., & LaQuaglia, M. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.449 · Cited by 389
Self-citationOsteogenic Sarcoma under the Age of Twenty-one
Marcove, R. C., Miké, V., HAJEK, J. V., LEVIN, A. G., & Hutter, R. V. P. (1970) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-197052030-00001 · Cited by 365
Sæter, G., Alvegård, T. A., Elomaa, I., Stenwig, A. E., Holmström, T., & Solheim, Ø. P. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1766 · Cited by 224
Killander, D., Dohlwitz, A., Engstedt, L., Franzén, S., Gahrton, G., GULLBRING, B., Holm, G., Holmgren, A., Höglund, S., KILLANDER, A., et al. (1976) · Cancer · doi:10.1002/1097-0142(197601)37:1 · Cited by 143
Self-citationBacci, G., Mercuri, M., Briccoli, A., Ferrari, S., Bertoni, F., Donati, D. M., Monti, C., Zanoni, A., Forni, C., & Manfrini, M. (1997) · PubMed · Cited by 109
Prognostic Variables in Osteosarcoma: A Multi-Institutional Study
Taylor, W. F., Ivins, J. C., Unni, K. K., Beabout, J. W., Golenzer, H. J., & Black, L. E. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.1.21 · Cited by 69
Central and peripheral myelinopathy associated with systemic neoplasia and chemotherapy
Mena, H., García, J. H., & Velandia, F. (1981) · Cancer · doi:10.1002/1097-0142(19811015)48:8 · Cited by 37
Current combined treatment of high-grade osteosarcomas.
Ta, D., & Dj, P. (1995) · PubMed · Cited by 12
Cited by
Sorted by citations
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S., Meltzer, P. S., & Gorlick, R. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,578
Self-citationOsteosarcoma treatment – Where do we stand? A state of the art review
Lütke, A., Meyers, P. A., Lewis, I. J., & Juergens, H. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,237
Self-citationBiology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N. M., Gebhardt, M. C., Teot, L. A., & Gorlick, R. G. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 670
Self-citationBeird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citationChemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456
Metadata
- Authors
- Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Journal of Clinical Oncology
- Published
- 1998-07
- Volume
- 16
- Issue
- 7
- Pages
- 2452-2458
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1946181835
- Cited by
- 294
- References
- 18
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 9 · 2019: 6 · 2018: 7 · 2017: 10 · 2016: 11 · 2015: 15 · 2014: 22 · 2013: 16 · 2012: 8
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Cancer Institute (CA-09512, T32CA009512)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- osteosarcoma, neoadjuvant chemotherapy, chemotherapy intensification, cisplatin, doxorubicin, high-dose methotrexate, bleomycin, cyclophosphamide, actinomycin D, histological response, tumor necrosis, event-free survival
- MeSH terms
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Bone Neoplasms, Child, Child, Preschool, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Female, Humans, Male, Methotrexate, Necrosis, Osteosarcoma, Time Factors, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
